Evidence map›Paper›PMID 37873189›Full record

ArticlebioRxiv : the preprint server for biology2023

ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer.

Yinshen Wee, Junhua Wang, Emily C Wilson, Coulson P Rich, Aaron Rogers, Zongzhong Tong, Evelyn DeGroot, Y N Vashisht Gopal, Michael A Davies, H Atakan Ekiz and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Yinshen WeeDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Junhua WangDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Emily C WilsonDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Coulson P RichDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Aaron RogersDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Zongzhong TongDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Evelyn DeGrootDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Y N Vashisht GopalDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
H Atakan EkizDepartment of Molecular Biology and Genetics, Izmir institute of Technology, Gulbahce, Urla, 35430, Izmir, Turkey.
Joshua K H TayDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Chris StubbenBioinformatics Shared Resource, Huntsman Cancer Institute, Salt Lake City, Utah.
Kenneth M BoucherCancer Biostatistics Shared Resource, Huntsman Cancer Institute, Salt Lake City, Utah.
Juan M OviedoDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Keke C FairfaxDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Matthew A WilliamsDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Sheri L HolmenHuntsman Cancer Institute, Salt Lake City, Utah.
Roger K WolffDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Allie H GrossmannDepartment of Pathology, University of Utah, Salt Lake City, Utah.
University of Utah · USThe University of Texas MD Anderson Cancer Center · USHuntsman Cancer Institute · USIzmir Institute of Technology · TR

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2019 to 2023
$10.3M
Efficacy of combined inhibition of BRAF, MEK, and FAK in melanoma patient derived xenograftsR01CA121118 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheri L Holmen · 2007 to 2026
$4.7M
Targeting Rheostatic Mechanisms of Melanoma ProgressionR37CA230630 · NCI · UNIVERSITY OF UTAH · PI Allie H. Grossmann · 2020 to 2026
$2.5M
Durable Schistosome induced metabolic alterations to the myeloid lineageR01AI158710 · NIAID · UNIVERSITY OF UTAH · PI AMIEL, EYAL, FAIRFAX, KEKE CELESTE · 2021 to 2024
$2.3M
The Role of the Small GTPase ARF6 in Oncogenic Signaling and TumorigenesisK08CA188563 · NCI · UNIVERSITY OF UTAH · PI GROSSMANN, ALLIE H. · 2015 to 2019
$902k
NCATS NIH HHS UM1 TR004409NCI NIH HHS K08 CA188563NCI NIH HHS P30 CA042014NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA121118NCI NIH HHS R37 CA230630NIAID NIH HHS R01 AI158710
6 · The paper itself

Abstract

Adaptive immune resistance (AIR) is a protective process used by cancer to escape elimination by CD8

Identifiers

PMID37873189
PMCPMC10592860
OpenAlexW4387244507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.